Adcendo plans to recruit patients for the study in the US and Europe. The company recently inked a deal potentially worth over $1bn with China-based Multitude for its tissue facto ...

The company is targeting its RPPA-based testing to biopharma firms as well as for clinical trial work and to clinicians to help guide therapy in cancer patients.

The market for B7-H3 inhibitors is expected to grow significantly in the coming years. This is due to the rising investment from leading pharma companies such as GSK, Merck, and others, the increasing ...

The company intends to start a registrational Phase II trial of pelareorep and chemotherapy combination for breast cancer in ...

The European Commission (EC) has granted approval for Daiichi Sankyo’s Vanflyta (quizartinib) for newly diagnosed fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) positive acute ...

Oncolytics stock soars as the company seeks an accelerated approval pathway for its lead candidate, pelareorep, to treat a ...

We're going to check out a few of the best picks from our screener tool. Overview: Daiichi Sankyo Company, Limited is a ...

Breaking news headlines, stories and live updates on current affairs from across the globe. Complete coverage on the latest top stories, business, sports, entertainment, and world politics news ...

Daiichi Sankyo submits Enhertu sNDA to Japan’s MHLF for patients with HER2 low or HER2 ultralow metastatic breast cancer: Tokyo Saturday, October 5, 2024, 10:00 Hrs [IST] Daiich ...

The trial was conducted across Germany, with patients' LDL-C levels measured at pretreatment, year one, and year two.

Japan Pruritus Therapeutics Market was valued at US$ 582.2 million in 2023 and is estimated to surpass the market size of US$ 1,011.5 million by 2032 at a CAGR of 6.33% during the forecast period 2024 ...

The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic ...